Welcome to our dedicated page for ABEONA THERAPEUTICS SEC filings (Ticker: ABEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ABEONA THERAPEUTICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ABEONA THERAPEUTICS's regulatory disclosures and financial reporting.
Abeona Therapeutics director Eric Crombez reported an open-market sale of 26,143 shares of common stock on May 15, 2026 at a weighted average price of $5.5325 per share. The sale was executed under a Rule 10b5-1 trading plan adopted on February 4, 2026, indicating the transactions were pre-arranged. Following this sale, Crombez directly holds 37,313 shares of Abeona Therapeutics common stock.
ABEONA THERAPEUTICS INC. Schedule 13G/A amendment reports that Nantahala Capital Management, LLC and its managing members, Wilmot B. Harkey and Daniel Mack, may be deemed beneficial owners of 5,775,350 shares of common stock as of March 31, 2026. The filing states these holdings represent 9.99% of the outstanding shares for each Reporting Person. The disclosure notes 762,298 shares of the total may be acquired within sixty days through the exercise of convertible securities. Shared voting and dispositive power over the 5,775,350 shares is recorded for Nantahala, Harkey and Mack.
ABEONA THERAPEUTICS INC. reports amended beneficial ownership by Nantahala Capital Partners. As of March 31, 2026, Nantahala may be deemed the beneficial owner of 3,333,757 shares, representing 5.82% of the class based on 57,049,023 shares outstanding as of December 31, 2025. The reported total includes 179,832 shares that may be acquired within sixty days upon exercise of securities. The filing shows shared voting and dispositive power over the full position.
ABEO filed a Form 144 reporting a proposed sale of Common Stock through Stifel Nicolaus on Nasdaq, dated 05/15/2026. The filing lists Restricted Stock Awards issued 08/13/2025 (6,326 shares) and 01/31/2026 (19,817 shares) that appear related to equity compensation.
Abeona Therapeutics reported its first meaningful commercial quarter for ZEVASKYN, generating $8.7 million in product revenue for the three months ended March 31, 2026. This compares to no revenue in the same period of 2025.
The company posted a net loss of $17.1 million, versus a $12.0 million loss a year earlier, as selling, general and administrative expenses rose to $19.5 million and research and development held roughly flat at $9.6 million. Loss from operations was $23.0 million.
Cash and cash equivalents were $61.4 million and short-term investments were $106.9 million, supporting total assets of $198.5 million and stockholders’ equity of $144.9 million. Management concluded existing capital resources are sufficient to fund operations for at least 12 months.
During the quarter Abeona signed a new license and joint development agreement with Reverence Enterprises for PSMA SIR-T T-cell therapy for prostate cancer, paying a $7.0 million upfront fee that was expensed as research and development. Warrant liabilities declined to $13.5 million as their fair value decreased.
Abeona Therapeutics reported first-quarter 2026 results highlighted by early ZEVASKYN commercialization and a new T‑cell therapy license. Net product revenue reached $8.7 million, a $6.3 million increase over the fourth quarter of 2025, driven by three ZEVASKYN patient treatments in the quarter.
Cost of sales was $2.7 million, while R&D totaled $9.6 million, including a $7.0 million upfront payment to in‑license PSMA‑SIR‑T, now ABO‑701. Selling, general and administrative expenses rose to $19.5 million as the company scaled commercial operations.
Abeona reported a net loss of $17.1 million, or $0.30 per share, compared with a $12.0 million loss a year earlier. Cash, cash equivalents and short‑term investments were $168.3 million as of March 31, 2026. The ZEVASKYN qualified treatment center network expanded to six sites, coverage policies now reach 95% of commercially insured U.S. lives, and the company plans to file an IND and begin first‑in‑human studies for ABO‑701 in the second half of 2027 while deprioritizing in‑house ophthalmology programs.
Abeona Therapeutics Inc. Chief Commercial Officer Madhav Vasanthavada reported an open-market sale of 5,548 shares of common stock at a weighted average price of $5.9613 per share. According to the filing, this sale was made specifically to cover tax obligations from the vesting of restricted stock awards, making it a mechanistic transaction rather than a discretionary portfolio change. Following the sale, Vasanthavada directly holds 313,071 shares of Abeona common stock, so the transaction represents a small portion of his overall reported holdings.
Abeona Therapeutics reports a 13G disclosure showing 3,100,000 shares of Common Stock beneficially owned, representing 5.4% of the class. The filing names AIGH Capital Management LLC, AIGH Investment Partners LLC and Orin Hirschman as reporting persons. The filing lists voting and dispositive power as sole for the full amount.